Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study

Cesar Giron‐Hernandez,1 Joong Hee Han,2 Roberta Alberio,3 Arun Singh,2 Maria Paz García-Portilla,4 Maurizio Pompili,5 R Karl Knight,2 Ute Richarz,6 Srihari Gopal,2,7 José Antunes8 1EMEA Medical Affairs, Janssen-Cilag, Issy-les-Moulineaux, France; 2Janssen Research & Development, LLC, Titusville, NJ,...

Descripció completa

Dades bibliogràfiques

Autors principals:	Giron‐Hernandez C, Han JH, Alberio R, Singh A, García-Portilla MP, Pompili M, Knight RK, Richarz U, Gopal S, Antunes J
Format:	Artigo
Idioma:	Inglês
Publicat:	Dove Medical Press 2023-04-01
Col·lecció:	Neuropsychiatric Disease and Treatment
Matèries:	europe long-acting injectable paliperidone palmitate 6-month relapse-free schizophrenia
Accés en línia:	https://www.dovepress.com/efficacy-and-safety-of-paliperidone-palmitate-6-month-versus-paliperid-peer-reviewed-fulltext-article-NDT
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!